ATP Binding Cassette transporters associated with chemoresistance: Transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients

Haematologica

Volumn 96, Issue 9, 2011, Pages 1293-1301

  Marzac, Christophe ^a,b   Garrido, Edith ^c   Tang, Ruoping ^a,b   Fava, Fanny ^a,b   Hirsch, Pierre ^a,b   de Benedictis, Cinzia ^d   Corre, Elise ^b   Lapusan, Simona ^b   Lallemand, Jean Yves ^c   Marie, Jean Pierre ^a,b   Jacquet, Eric ^c   Legrand, Ollivier ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

ABC genes; Acute myeloid leukemia; Adult; AML; MDR

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADENOSINE TRIPHOSPHATASE BINDING CASSETTE A2 GENE; ADENOSINE TRIPHOSPHATASE BINDING CASSETTE B1 GENE; ADENOSINE TRIPHOSPHATASE BINDING CASSETTE B6 GENE; ADENOSINE TRIPHOSPHATASE BINDING CASSETTE C13 GENE; ADENOSINE TRIPHOSPHATASE BINDING CASSETTE G1 GENE; ADENOSINE TRIPHOSPHATASE BINDING CASSETTE G2 GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RESISTANCE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; CLUSTER ANALYSIS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; YOUNG ADULT;

EID: 80052382195     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.031823     Document Type: Article

References (48)

1. Baudard M, Beauchamp-Nicoud A, Delmer A, Rio B, Blanc C, Zittoun R, et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia. 1999;13(10):1481-90.
2. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991;78(3):586-92.
3. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/Pglycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94(3): 1086-99.
4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89(9):3323-9.
5. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 1996;88(4):1198-205.
6. Liu Yin JA, Wheatley K, Rees JK, Burnett AK; UK MRC Adult Leukemia Working Party. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol. 2001;113(3):713-26
7. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 2002;100(4):1224-32.
8. Solary E, Drenou B, Campos L, de Crémoux P, Mugneret F, Moreau P, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood. 2003;102(4):1202-10.
9. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol. 2004;22(13):1078-86.
10. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001;98(12):3212-20.
11. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res. 2005;11(6):2320-6.
12. Raaijmakers MH. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia Leukemia. 2007;21(10):2094-102.
13. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, et al. MRP3, BCRP and Pgp, but not MRP1, MRP2 and MRP5 activity, are Prognostic factors in adult acute myeloid. Clin Cancer Res. 2005;11 (21):7764-72.
14. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, et al. BCRP and Pgp in 149 adult acute myeloid leukemias. Clin Cancer Res. 2004;10(23):7896-902.
15. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res. 2006;12(14 Pt 1):4357-63.
16. van der Kolk DM, Vellenga E, Scheffer GL, Müller M, Bates SE, Scheper RJ, et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood. 2002;99(10):3763-70.
17. Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 1999;94(3):1046-56.
18. van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE, et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res. 2000;6(8):3205-14.
19. de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ, et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38-cells. Leukemia. 2006;20(4): 750-4.
20. Willemze R, Suciu S, Mandelli F, Labar B, Marie JP, Mistrik M, et al. High Dose (HDAraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups). Blood. 2008,112: Abstract 134.
21. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106(1):27-34.
22. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17(12):2318-57.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.
24. Marzac C, Teyssandier I, Calendini O, Perrot JY, Faussat AM, Tang R, et al. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. Clin Cancer Res. 2006;12(23):7018-24.
25. Tang R, Hirsch P, Fava F, Lapusan S, Marzac C, Teyssandier I, et al. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. Blood. 2009;114(14):2993-3000.
26. Sturm A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics. 2002;18(1):207-8.
27. Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2006;5(8):1986-94.
28. Mack JT, Brown CB, Tew KD. ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opin Ther Targets 2008;12(4):491-504.
29. Boonstra R, Timmer-Bosscha H, van Echten-Arends J, van der Kolk DM, van den Berg A, de Jong B, et al. Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer. 2004;90(12):2411-7.
30. Peeters SD, van der Kolk DM, de Haan G, Bystrykh L, Kuipers F, de Vries EG, et al. Selective expression of cholesterol metabolism genes in normal CD34+CD38-cells with a heterogeneous expression pattern in AML cells. Exp Hematol. 2006;34(5):622-30.
31. Eckford PD, Sharom FJ. Interaction of the Pglycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry. 2008;47(51):13686-98.
32. Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol. 2004;66(5):1332-9.
33. Tang L, Bergevoet SM, Gilissen C, de Witte T, Jansen JH, van der Reijden BA, et al Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells. BMC Pharmacol. 2010;10:12.
34. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65(10):4320-33.
35. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2006;99(1):9-17.
36. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004; 64(4):1403-10.
37. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH, et al. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One. 2007;2(8):e798.
38. Heimerl S, Bosserhoff AK, Langmann T, Ecker J, Schmitz G. Mapping ATP-binding cassette transporter gene expression profiles in melanocytes and melanoma cells. Melanoma Res. 2007;17(5):265-73.
39. Yabuuchi H, Takayanagi S, Yoshinaga K, Taniguchi N, Aburatani H, Ishikawa T. ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. Biochem Biophys Res Commun 2002;299(3):410-7.
40. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol. 1998;102(4):1015-24.
41. Sood AK, Sorosky JI, Squatrito RC, Skilling JS, Anderson B, Buller RE. Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies. Neoplasia 1999; 1(2):118-22.
42. Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(23):4508-16.
43. Chan HS, DeBoer G, Thiessen JJ, Budning A, Kingston JE, O'Brien JM, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996;2(9):1499-508.
44. Burcu M, O'Loughlin KL, Ford LA, Baer MR. Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008;22(11):2110-5.
45. Chau M, Christensen JL, Ajami AM, Capizzi RL. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoproteinmediated efflux. Leuk Res. 2008;32(3):465-73.
46. Schlenk RF, Döhner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol. 2009;16(2):98-104.
47. Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Wessels H, de Witte T. Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance. Blood. 1999;94(7):2414-23.
48. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T; SHG AML96 Study Group. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol. 2005;128(3):324-32.